EUVIMEDEUVIMED entdecken
Crossref

Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats

Dexin Zhang, Rui Zheng, Zhoutong Chen, Liren Wang, Xi Chen, Lei Yang, Yanan Huo, Shuming Yin, Dan Zhang, Jiaxin Huang, Xingang Cui, Dali Li und 1 weitere

Science China Life Sciences · 2024

DOI: 10.1007/s11427-024-2697-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science China Life Sciences, 2024. Verfasst von Dexin Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. Hauptthemen laut MEDLINE: Gene Editing, Nanoparticles, Hyperoxaluria, Primary, Oxalates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary hyperoxaluria type 1 (PH1) is a severe hereditary disease, leading to the accumulation of oxalate in multiple organs, particularly the kidney. Hydroxyacid oxidase 1 (HAO1), a pivotal gene involved in oxalate production, is an approved target for the treatment of PH1. In this study, we demonstrated the discovery of several novel therapeutic sites of the Hao1 gene and the efficient editing of Hao1 c.290-2 A in vivo with lipid nanoparticles (LNP) delivered adenine base editing (ABE) mRNA. A single infusion of LNP-ABE resulted in a near-complete knockout of Hao1 in the liver, leading to the sustainable normalization of urinary oxalate (for at least 6 months) and complete rescue of the patho-physiology in PH1 rats. Additionally, a significant correlation between Hao1 editing efficiency and urinary oxalate levels was observed and over 60% Hao1 editing efficiency was required to achieve the normalization of urinary oxalate in PH1 rats. These findings suggest that the LNP-mediated base-editing of Hao1 c.290-2 A is an efficient and safe approach to PH1 therapy, highlighting its potential utility in clinical settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingNanoparticlesHyperoxaluria, PrimaryOxalatesAnimalsRatsMaleRats, Sprague-DawleyLiverLipidsDisease Models, AnimalGenetic TherapyKidneyLiposomes

Stichwörter der Autor:innen

base editinghydroxyacid oxidase 1lipid nanoparticlesprimary hyperoxaluria type 1

Substanzen

OxalatesLipid NanoparticlesLipidsLiposomes

Autor:innen und Institutionen

  • Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China.
  • Department of Urology, Children's Hospital of Fudan University, Shanghai, 201100, China.
  • Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai,…
  • Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. cuixingang@xinhuamed.com.cn.
  • Department of Urology, Children's Hospital of Fudan University, Shanghai, 201100, China. genghongquan@fudan.edu.cn.

Zitieren

APA

Zhang, D., Zheng, R., Chen, Z., Wang, L., Chen, X., Yang, L., Huo, Y., Yin, S., Zhang, D., Huang, J., Cui, X., Li, D., & Geng, H. (2024). Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats. Science China Life Sciences. https://doi.org/10.1007/s11427-024-2697-3

Vancouver

Zhang D, Zheng R, Chen Z, Wang L, Chen X, Yang L, et al. Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats. Science China Life Sciences. 2024. doi:10.1007/s11427-024-2697-3

BibTeX
@article{Zhang2024,
  author = {Zhang, Dexin and Zheng, Rui and Chen, Zhoutong and Wang, Liren and Chen, Xi and Yang, Lei and Huo, Yanan and Yin, Shuming and Zhang, Dan and Huang, Jiaxin and Cui, Xingang and Li, Dali and Geng, Hongquan},
  title = {Lipid nanoparticle-mediated base-editing of the Hao1 gene achieves sustainable primary hyperoxaluria type 1 therapy in rats},
  journal = {Science China Life Sciences},
  year = {2024},
  doi = {10.1007/s11427-024-2697-3}
}
Kostenlos starten →